Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have entered into a non-exclusive licensing agreement. The deal covers Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies, enabling SignalChem to incorporate these AI-designed proteins into its custom luminescent assay development and protein-fusion services for third-party researchers. This collaboration expands SignalChem's specialized CRO capabilities and aligns with Sino Biological's broader strategy of integrating AI-enabled technologies across its global life science tools and services portfolio.
The significance of this agreement lies in its potential to accelerate drug discovery and life science research. By leveraging Monod Bio's AI-designed proteins, SignalChem can offer researchers more efficient pathways to high-quality discovery candidates. Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized that incorporating these technologies into SignalChem's custom assay platform will help researchers obtain high-quality discovery candidates more rapidly. He noted that this agreement strengthens their ability to address complex biological questions and advance research programs efficiently.
Monod Bio's LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows. Daniel Silva Manzano, PhD, CEO of Monod Bio, highlighted that SignalChem and Sino Biological possess the scientific expertise, customer reach, and service infrastructure to bring these technologies to a broad customer base. He stated that this partnership expands the reach of their platform and reinforces the value of the Monod Inside model, which integrates AI-designed proteins into commercial products and services.
The licensing agreement is a strategic move for Sino Biological, which aims to incorporate AI-enabled technologies into its portfolio. SignalChem Biotech, a specialized provider of reagents and CRO services, will now be able to offer these advanced tools to its clients. Sino Biological, with facilities across Asia, North America, and Europe, is committed to providing innovative life science tools. The company notes that while the development of related business may be affected by market demand, the revenue associated with this licensing agreement is not expected to have a material impact on overall financial performance due to the company's broad product portfolio.
For more information about Sino Biological and its services, visit www.sinobiological.com. For more information about Monod Bio and its AI-designed proteins, visit monod.bio.
